Arax Advisory Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Arax Advisory Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.17M	Buy	13,844 +13,005	+1,550%	+$3.92M	0.03%	543
2026 Q1	$275K	Buy	839 +161	+24%	+$54.8K	0.01%	919
2025 Q4	$270K	Sell	678 -12,407	-95%	-$5.49M	0.01%	885
2025 Q3	$5.97M	Buy	13,085 +12,935	+8,623%	+$5.27M	0.09%	193
2025 Q2	$48.9K	Buy	150 +65	+76%	+$18K	﹤0.01%	1245
2025 Q1	$23K	Sell	85 -396	-82%	-$102K	﹤0.01%	1245
2024 Q4	$113K	Sell	481 -4	-0.8%	-$1.05K	0.01%	646
2024 Q3	$133K	Buy	485 +4	+0.8%	+$1.04K	0.01%	436
2024 Q2	$117K	Buy	+481	New	+$75.9K	0.01%	445
2024 Q1	–	Sell	-21	Closed	-$4.02K	–	1315
2023 Q4	$4.02K	Buy	21 +13	+163%	+$2.21K	﹤0.01%	923
2023 Q3	$1.42K	Buy	8 +5	+167%	+$954	﹤0.01%	1073
2023 Q2	$570	Sell	3 -5	-63%	-$991	﹤0.01%	1191
2023 Q1	$1.6K	Hold	8	–	–	﹤0.01%	1023
2022 Q4	$1.9K	Hold	8	–	–	﹤0.01%	954
2022 Q3	$2K	Buy	+8	New	+$1.53K	﹤0.01%	934

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's ALNY Position: Q2 2026 in Review

Arax Advisory Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 1,550% in Q2 2026, buying an estimated $3.92M and bringing the position to 13,844 shares worth $4.17M. The position accounts for 0.03% of the portfolio, ranked #543.

Arax Advisory Partners first reported a position in ALNY in Q3 2022 and has held it in 15 quarters since. The position peaked at $5.97M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Arax Advisory Partners held 13,844 shares of Alnylam Pharmaceuticals worth $4.17M as of Q2 2026.
Arax Advisory Partners bought 13,005 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $3.92M.
Alnylam Pharmaceuticals made up 0.03% of Arax Advisory Partners's portfolio in Q2 2026, its #543 holding.
Arax Advisory Partners first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Arax Advisory Partners's Alnylam Pharmaceuticals position peaked at $5.97M in Q3 2025.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.